Category: Kratom

Idaho lawmakers have revised a proposed kratom regulation bill after hours of emotional testimony from families, police, medical professionals and industry representatives. The Idaho Kratom Consumer Protection and Safety Act, sponsored by Sen. Tammy Nichols, R-Middleton, would limit sales to adults 21 and older, restrict products to natural leaf, and ban adulterated or synthetic kratom containing high levels of 7-hydroxymitragynine.

Amendments approved Thursday add stricter labeling rules, including batch numbers, ingredient lists and prominent medical warnings that kratom may be habit-forming and has not been evaluated by the FDA, and push the effective date to Jan. 1, 2027. The debate runs alongside a separate House bill seeking an outright ban, leaving Idaho’s kratom policy hinging on upcoming Senate and House votes.

Read the original report from the Lewiston Tribune.

Kratom will become legal to sell in Rhode Island on April 1 under the Rhode Island Kratom Act, which restricts sales to adults 21 and older and already requires products to be kept behind the counter, accessible only to store employees. Now, a new bill, H7518, would go further by mandating that all kratom products be stored in locked cases until the point of sale. Supporters frame the move as a security measure aimed at preventing theft and youth access, noting that Rhode Island recorded 10 overdose deaths involving kratom between 2020 and 2024. The proposal comes as other states tighten rules, with Louisiana banning kratom and Connecticut designating it a Schedule 1 controlled substance, underscoring a growing national divide over the herb’s place in retail. For more, see the original USA Today coverage of the debate over kratom security in Rhode Island.

Speaker Matt Hall plans to replace a bipartisan regulatory bill with a sweeping ban on kratom. In a statement, the AKA said the procedural maneuver sidestepped standard committee review and curtailed public testimony from Michigan consumers.​

The original Kratom Consumer Protection Act would have imposed safeguards such as age limits, product purity standards, and clear alkaloid labeling, but was instead converted into a full prohibition. AKA policy fellow Mac Haddow warned that an outright ban could push consumers toward unregulated markets and fails to distinguish natural kratom from synthetic compounds linked to greater health risks. The group cited National Institute on Drug Abuse findings to argue for a regulated market and urged lawmakers to restore a science-based framework.​

Read the full release at Reuters.

Tennessee mother of five Jessica Cosby is urging state lawmakers to reconsider proposed crackdowns on kratom, saying the measures would devastate chronic pain patients while fentanyl continues to drive overdose deaths statewide. Two bills, SB2417 and SB1655, would sharply restrict or criminalize possession and sale of kratom products, with SB1655 elevating simple possession to a felony offense. Cosby, who lives with multiple debilitating pain conditions, says it’s is the only option that lets her stay active with her children and off more dangerous drugs. She argues lawmakers have not presented clear data showing kratom is causing a public health crisis and calls instead for regulated, evidence-based policy. Read the original column in the Clarion Ledger.

Virginia lawmakers are moving forward with House Bill 360, a measure that would sharply restrict kratom products containing the compound 7‑hydroxymitragynine, despite pushback from harm-reduction advocates. Supporters of kratom say the bill, framed as consumer protection, would effectively ban many products that adults currently use to manage pain and opioid withdrawal symptoms, driving demand to an unregulated black market.​

Citing federal data, critics note that more than 1 billion servings of 7‑OH have been consumed in the U.S. with only 82 reported adverse events, and no clear evidence of a unique overdose crisis tied to the compound. They argue Virginia should tighten age limits, labeling and testing standards instead, and urge Gov. Abigail Spanberger to veto HB360 in favor of measured regulation over prohibition.

See The Virginian-Pilot for more.

Kratom, a Southeast Asian plant long used for pain relief and mood support, is at the center of a growing regulatory battle in the United States. Advocates argue consumers need protection from adulterated products, not prohibition, warning that a ban could criminalize users and cut off a potential tool in addressing opioid dependence. The Kratom Consumer Protection Act, already adopted in several states, seeks to mandate testing, clear labeling and age restrictions while banning dangerous additives and artificially boosted alkaloid levels. Federal health agencies, including the National Institute on Drug Abuse, are funding studies that suggest kratom may offer pain relief and support for opioid and alcohol use disorders with lower abuse potential than traditional opioids. The fact sheet underpinning these claims is available at kratomanswers.org

An Idaho bill aimed at banning synthetic kratom while creating safeguards for natural kratom products has stalled in a Senate committee, exposing a sharp divide over how the state should respond to the controversial substance. Supporters argue the legislation would regulate labeling, testing, and age limits to keep unsafe, lab-made kratom derivatives off the market while allowing responsible businesses to operate. Opponents are pushing for a blanket ban, claiming kratom in any form poses unacceptable risks. Industry advocates counter that prohibition would drive sales underground and strip consumers of access to regulated products. The bill’s future is uncertain as lawmakers weigh competing public health and economic arguments. You can read the original report from KTVB’s 7 Investigates here.

Kansas City’s council is set to vote today on an ordinance that would outlaw synthetic 7-OH kratom while imposing tighter controls on natural kratom sales. The measure targets lab-made 7-OH and other synthetic alkaloids, which officials say have fueled a wave of dangerous “gas station heroin” products in local stores. Natural, unadulterated kratom could still be sold, but only to customers over 21 and under a stricter licensing regime.

The proposal follows weeks of emotional testimony from residents and warnings from health officials, alongside concerns from others about unintended consequences of a ban. Mayor Quinton Lucas has called the ordinance a step in the right direction and there is broad expectation it will pass. A neighboring suburb, Independence, is considering a similar move next month. Read the original report at KSHB 41.

Utah lawmakers are advancing three separate proposals to address kratom, a Southeast Asian plant often marketed for pain relief and energy. Republican Sen. Evan Vickers introduced SB48, targeting regulation of the chemical 7‑Hydroxymitragynine, and SB101, which would impose a tax on kratom products. Meanwhile, Sen. Michael McKell proposed SB45, which would classify kratom and its derivatives as Schedule I substances—effectively banning them.

Supporters of regulation argue for evidence-based oversight, while opponents of a full ban cite kratom’s role in managing chronic pain and opioid withdrawal. All three bills have cleared initial legislative hurdles and now head to further debate.

Read the full story by Ethan Rauschkolb at KUER.org.

The Spokane City Council has postponed a proposed ban on the plant-based drug kratom while Washington state lawmakers debate broader regulations.

Instead, council members opted to wait at least two months as two Senate bills move forward. Senate Bill 6287 would set labeling rules, restrict sales to those over 21, and allow local bans. Senate Bill 6196 proposes a steep 95% tax on kratom sales and state licensing for distributors.

If the state Legislature makes no progress by spring, Spokane may revisit its own ban.
Read the full report at The Spokesman-Review.

Montana lawmakers are exploring ways to regulate kratom before the 2027 legislative session amid growing concern over synthetic versions of the drug. Use of both natural and synthetic kratom products has surged nationwide in recent decades, prompting 18 states to regulate manufacturing and sales and six to classify certain compounds as controlled substances as of April 2025.

Montana has no statewide laws on kratom, a gap members of the Law and Justice Interim Committee highlighted during a Jan. 14 hearing. A 2025 bill to restrict high levels of 7-hydroxymitragynine and bar sales to those under 21 stalled in committee, leaving regulation to local governments such as the Blackfeet Tribal Business Council and Yellowstone County. Lawmakers plan to reconvene in March after studying approaches in other states, including an emergency 180-day ban on synthetic kratom by the Ohio Board of Pharmacy. Read the original report at the Daily Inter Lake.

The American Kratom Association (AKA) has criticized the Ohio Board of Pharmacy for its unanimous decision to classify natural kratom’s key compound, mitragynine, as a controlled substance — a move the group calls “scientifically unjustified.”

In a statement, the AKA expressed deep concern that the Board reached its decision “without a single question” during deliberations, relying on what it described as outdated federal data long rejected by health officials. Both HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Dr. Marty Makary have clarified that enforcement should target synthetic 7-hydroxymitragynine products, not natural kratom leaf. The AKA has urged Ohio lawmakers to intervene and reverse the decision, calling it a threat to consumers who use kratom as a safer alternative to opioids.

Read the full statement from the American Kratom Association.

The Berkeley County Coroner’s Office in South Carolina will hold a public forum on Tuesday to discuss kratom, a plant-based substance often used for pain relief and anxiety. The event, hosted in partnership with the Ernest E. Kennedy Center and Wake Up Carolina, aims to give residents a clearer understanding of kratom’s local impact and the latest medical findings surrounding its use.

While some people use kratom to manage pain or opioid withdrawal, the U.S. Food and Drug Administration warns it is not approved as a dietary supplement. The free town hall will include expert-led discussions and community data.

Read more via MSN News.

New York Governor Kathy Hochul has signed two new laws regulating the sale and labeling of kratom, a psychoactive plant-based substance. The legislation bans sales to anyone under 21 and requires warning labels stating possible health risks, including agitation, liver damage, and death. Advertising kratom as “all-natural” is also prohibited.

The new laws follow advocacy from Saratoga County resident Cari Scribner, whose son Nickolas died in 2024 after using the substance. Hochul credited Scribner’s efforts in pushing the legislation forward, calling her a “fierce advocate” for public health.

Violators face fines up to $500 for retailers and $1,000 for manufacturers. The labeling requirements take effect in 2026. Full story available at Saratoga TODAY.

New York State has introduced stricter controls on kratom, an herbal product often marketed as a natural stimulant or pain reliever. Governor Kathy Hochul signed two bills aimed at improving public safety and product transparency. The first measure bans sales of kratom to anyone under 21, with fines up to $500 per offense. The second requires all kratom products to display warning labels outlining addiction risks, possible drug interactions, and a full list of ingredients.

Health officials warn that concentrated forms of kratom, or products adulterated with synthetic compounds, can act like opioids and pose serious health risks. The New York State Department of Health will begin monitoring these substances more closely.

Read the full story at Sun Community News.

Fresno city officials have reversed course on a proposed kratom ban, instead approving an ordinance that permits the sale of natural-leaf kratom to adults while banning concentrated derivatives. Under the new law, taking effect in January 2026, retailers may sell kratom products only to customers aged 21 and over, provided levels of the psychoactive compound 7-hydroxymitragynine (7-OH) remain below 1% of total alkaloids.

Councilmember Nelson Esparza, who introduced the amendment, said the goal was to balance public safety with respect for kratom’s traditional cultural use. Fresno County is considering a similar policy with a 2% 7-OH limit.

Read the full report by Tim Sheehan via KVPR.

DENVER – Colorado’s new Daniel Bregger Act is reshaping the conversation around kratom by tightening safety rules without banning the herbal supplement that many users credit with easing pain and opioid withdrawal. The law caps highly concentrated 7-hydroxymitragynine products, restricts sales to adults over 21 and requires clearer labeling, moves designed to steer consumers toward traditional leaf-based kratom and away from risky gas-station style shots.​

Researchers, backed by multimillion-dollar NIH funding, are simultaneously probing kratom’s alkaloids as candidates for safer pain medicines and treatments for opioid dependence. Early work suggests some compounds may relieve pain and withdrawal with less danger of respiratory depression, strengthening calls to regulate, not prohibit, kratom. A fuller exploration of these developments appears in The Conversation’s analysis.

As Los Angeles County health officials move to ban the sale of kratom and synthetic 7-OH, advocates warn that sweeping prohibition may not be the answer. In a recent letter to the editor, Yael Ossowski of the Consumer Choice Center argues that states like Rhode Island have shown a better path—enacting dosage standards, labeling requirements, and age restrictions, rather than criminalizing millions of users. Ossowski highlights that overdose cases linked to kratom and 7-OH often involve multiple substances, making transparent market rules more essential than ever. The letter urges policymakers to focus on safe regulation instead of outright bans, promoting consumer safety and clarity. Read the original letter in the Los Angeles Times for further details.